At a non-toxic dose (0.5 mg/ml), FM markedly reduced the activation of NF-κB and STAT3 in the mixture of HCC and CD8+NKG2D+ cells (Fig. 2b), and downregulated the expression of TNF-α and IL-6 (Fig. 2c). The gene discussed is STAT3; the disease is hepatocellular carcinoma.